Demographic and plasma vascular endothelial growth factor (VEGF) data obtained from patients with diabetic macular oedema
| DME | Baseline | 7 days | 4 weeks | p Value* | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age (SEM) | n (Males n) | Mean (SEM) VEGF pg/ml | Median | 25th/75th Percentile | n (Males n) | Mean (SEM) VEGF pg/ml | Median | 25th/75th Percentile | n (Males n) | Mean (SEM) VEGF pg/ml | Median | 25th/75th Percentile | ||
| Bevacizumab | 66.7 (2.0) | 10 (5) | 72.2 (20.4) | 49.0 | 20.5/116.5 | 9 (4) | 13.7 (4.0) | 11.0 | 4.5/17.5 | 8 (4) | 17.1 (3.7) | 16.0 | 9.2/28.3 | 0.002 |
| Ranibizumab | 67.2 (3.3) | 10 (8) | 43.5 (16.6) | 25.5 | 23.5/39.0 | 9 (7) | 52.9 (24.1) | 24.0 | 16.0/62.0 | 7 (6) | 41.7 (10.6) | 33.0 | 20.0/52.0 | 0.565 |
| Pegaptanib | 68.0 (6.4) | 10 (8) | 57.1 (15.6) | 62.5 | 26.8/134.3 | 9 (8) | 57.1 (14.5) | 43.0 | 25.5/75.0 | 8 (7) | 76.9 (19.9) | 62.5 | 26.8/134.3 | 0.798 |
*p Values for comparison of VEGF levels using Friedman test. p Values of less than 0.05 were considered to indicate statistical significance.
DME, diabetic macular oedema.